This suggests that PDE-5 inhibitors and GC-C agonists might also be effective in treating PI-IBS or IBD patients, where the diarrhea is associated with a dysfunctional epithelial barrier rather than hypersecretion. The gene discussed is GUCY2C; the disease is irritable bowel syndrome.